2015 Annual Meeting of the European Association for the Study of the Liver*

April 22-26, 2015; Vienna, Austria
CCO’s Independent Conference Coverage of EASL 2015 includes Capsule Summaries, expert faculty analysis of key studies, and downloadable slides.

HCV Investigational Therapies

Capsules

High efficacy observed regardless of presence of cirrhosis, although patients with high baseline HCV RNA level were more likely to experience virologic failure.

Released: April 25, 2015

Efficacy appeared reduced in cirrhotic patients although both groups tolerated treatment well.

Released: April 29, 2015

12-week regimen of daclatasvir, sofosbuvir, and ribavirin associated with SVR12 rates of 83% overall in patients with advanced cirrhosis and 94% in patients with posttransplantation recurrence, high SVR rates across genotypes.

Released: April 28, 2015

Shortening treatment duration to 8 weeks resulted in reduced rates of cure and more frequent relapse.

Released: April 29, 2015

High efficacy observed in all patient subgroups, including hemodialysis patients.

Released: April 29, 2015

DAA-experienced patients may also benefit from this novel regimen, although a longer treatment duration likely necessary in this population.

Released: April 30, 2015

In the subset of study patients who have reached SVR4, extended treatment duration of 24 weeks appeared to provide greater efficacy vs 12 weeks in this difficult-to-treat population.

Released: April 26, 2015

The SVR12 rate in this PI-experienced population was 96% overall and 95% among patients with previous virologic failure; 3 patients relapsed with treatment-emergent NS3 and NS5A RAVs.

Released: April 24, 2015

In this phase II trial, 8-week therapy was promising, even in some cirrhotic groups, but SVR12 rates declined to below 90% when treatment duration was reduced further, dropping substantially with 4-week regimen.

Released: April 27, 2015

Efficacy also observed in genotype 4 HCV–infected patients receiving grazoprevir/elbasvir with or without ribavirin; evaluation of efficacy in genotypes 5 and 6 require additional patient numbers.

Released: April 25, 2015

SVR rates were consistently high in patients treated with a 16-week grazoprevir/elbasvir plus ribavirin regimen; no relapses observed in this arm.

Released: April 26, 2015

No HCV genotype/subtype or other patient parameter was associated with a decrease in treatment efficacy for this coinfected population.

Released: April 26, 2015
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Educational grant provided by:
AbbVie
Gilead Sciences
Merck & Co., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?